Albert Rizzo, MD, FACP, chief medical officer for the American Lung Association, discusses the use of forced expiratory volume in 1 second (FEV1) /forced vital capacity (FVC) for the diagnosis of chronic obstructive pulmonary disease.
Albert Rizzo, MD, FACP, chief medical officer for the American Lung Association, discusses the use of forced expiratory volume in 1 second (FEV1) /forced vital capacity (FVC) for the diagnosis of chronic obstructive pulmonary disease.
Transcript
Do you see any downfalls with using a fixed FEV1/FCV ratio for COPD diagnosis?
I think spirometry is recognized as still a good tool to identify the airflow obstruction. The most recent guidelines for treating COPD still talk about spirometry, but they don’t put it as the number 1 defining factor. We look at symptoms and exacerbations now. So, FEV1 and FEV1/FCV ratio can still be used to help with certain severity measures and could be a sign of increasing exacerbation, but it’s not the tool we really direct our treatment at.
We look at quality of life and symptoms. For example, can a patient walk at the same level as somebody their age? If they can’t and are more severely impaired, they fall under a category that needs more bronchodilatation. If they are hospitalized for their COPD, now they’re in a category where exacerbations tend to be more common. They need not just bronchodilators, they need inhaled corticosteroids as well to control the exacerbations.
To your original question, the FEV1/FVC ratio has some of its faults. Some people feel that it overdiagnoses COPD in the elderly and underdiagnoses in the younger individuals, but I think that spirometry should be used in conjunction with what the patient’s presenting with—certain symptoms, certain findings on x-ray, certain physical exam findings. So, it’s part of the overall tools that a physician uses to say this patient has a degree of COPD they may want treatment.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More